WallStreetZenWallStreetZen

NASDAQ: BCAX
Bicara Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BCAX

Based on 6 analysts offering 12 month price targets for Bicara Therapeutics Inc

Min Forecast
$11.00-35.18%
Avg Forecast
$27.17+60.09%
Max Forecast
$40.00+135.71%

Should I buy or sell BCAX stock?

Based on 6 analysts offering ratings for Bicara Therapeutics Inc.

Buy
Strong Buy
2 analysts 33.33%
Buy
2 analysts 33.33%
Hold
2 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BCAX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates BCAX as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their BCAX stock forecasts and price targets.

BCAX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-13
lockedlocked$00.00+00.00%2026-01-08
lockedlocked$00.00+00.00%2025-12-18
lockedlocked$00.00+00.00%2025-11-11
lockedlocked$00.00+00.00%2025-08-22
Piper Sandler
Top 13%
88
Strong BuyInitiates Coverage On$36.00+112.14%2025-08-19

1 of 1

Forecast return on equity

Is BCAX forecast to generate an efficient return?

Company
-35.33%
Industry
349.65%
Market
205.72%
BCAX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BCAX forecast to generate an efficient return on assets?

Company
-33.51%
Industry
121.36%
BCAX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BCAX earnings per share forecast

What is BCAX's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$3.08-157.27%
Avg 2 year Forecast
-$3.20-159.64%
Avg 3 year Forecast
-$2.40-144.64%

BCAX revenue forecast

What is BCAX's revenue in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$11.9M

BCAX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BCAX$16.97$27.17+60.09%Buy
XNCR$13.00$24.88+91.35%Strong Buy
AVBP$22.88$40.25+75.92%Strong Buy
BBOT$11.39$23.83+109.24%Buy
URGN$19.23$36.33+88.94%Strong Buy
View Top Biotech Stocks

Bicara Therapeutics Stock Forecast FAQ

Is Bicara Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: BCAX) stock is to Buy BCAX stock.

Out of 6 analysts, 2 (33.33%) are recommending BCAX as a Strong Buy, 2 (33.33%) are recommending BCAX as a Buy, 2 (33.33%) are recommending BCAX as a Hold, 0 (0%) are recommending BCAX as a Sell, and 0 (0%) are recommending BCAX as a Strong Sell.

If you're new to stock investing, here's how to buy Bicara Therapeutics stock.

What is BCAX's earnings growth forecast for 2026-2028?

(NASDAQ: BCAX) Bicara Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.82%.

Bicara Therapeutics's earnings in 2026 is -$121,521,000.On average, 14 Wall Street analysts forecast BCAX's earnings for 2026 to be -$168,487,365, with the lowest BCAX earnings forecast at -$185,217,773, and the highest BCAX earnings forecast at -$132,873,620. On average, 11 Wall Street analysts forecast BCAX's earnings for 2027 to be -$175,455,629, with the lowest BCAX earnings forecast at -$220,113,875, and the highest BCAX earnings forecast at -$122,519,831.

In 2028, BCAX is forecast to generate -$131,312,334 in earnings, with the lowest earnings forecast at -$140,658,135 and the highest earnings forecast at -$126,546,305.

What is BCAX's revenue growth forecast for 2026-2028?

(NASDAQ: BCAX) Bicara Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.2%.

Bicara Therapeutics's revenue in 2026 is $0.On average, 13 Wall Street analysts forecast BCAX's revenue for 2026 to be $0, with the lowest BCAX revenue forecast at $0, and the highest BCAX revenue forecast at $0. On average, 10 Wall Street analysts forecast BCAX's revenue for 2027 to be $0, with the lowest BCAX revenue forecast at $0, and the highest BCAX revenue forecast at $0.

In 2028, BCAX is forecast to generate $651,905,205 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,026,473,325.

What is BCAX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BCAX) forecast ROA is -33.51%, which is lower than the forecast US Biotechnology industry average of 121.36%.

What is BCAX's Price Target?

According to 6 Wall Street analysts that have issued a 1 year BCAX price target, the average BCAX price target is $27.17, with the highest BCAX stock price forecast at $40.00 and the lowest BCAX stock price forecast at $11.00.

On average, Wall Street analysts predict that Bicara Therapeutics's share price could reach $27.17 by Jan 13, 2027. The average Bicara Therapeutics stock price prediction forecasts a potential upside of 60.09% from the current BCAX share price of $16.97.

What is BCAX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BCAX) Bicara Therapeutics's current Earnings Per Share (EPS) is $5.37. On average, analysts forecast that BCAX's EPS will be -$3.08 for 2026, with the lowest EPS forecast at -$3.38, and the highest EPS forecast at -$2.43. On average, analysts forecast that BCAX's EPS will be -$3.20 for 2027, with the lowest EPS forecast at -$4.02, and the highest EPS forecast at -$2.24. In 2028, BCAX's EPS is forecast to hit -$2.40 (min: -$2.57, max: -$2.31).

What is BCAX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BCAX) forecast ROE is -35.33%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.